Ifetroban for Preventing Cancer Spread

Recruiting in Palo Alto (17 mi)

Overseen bySonya Reid

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Vanderbilt-Ingram Cancer Center

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial studies ifetroban, a drug that makes blood cells less sticky, in patients with high-risk malignant tumors. The goal is to see if it can safely help prevent cancer from spreading after initial treatments.

Eligibility Criteria

Adults over 18 with stage I to III solid tumors at high risk of recurrence after treatment can join. They must have finished all standard cancer treatments within the past 120 days, be in good enough health (ECOG status 0-2), and have recovered from previous therapies. Participants need normal organ function tests, not be on blood thinners or anti-platelet drugs, and agree to use two contraception methods if applicable.

Inclusion Criteria

Administration of an investigational agent prior to enrollment needs to be completed at least 30 days prior to enrollment

I have recovered from my last cancer treatment's side effects.

Platelet count must be at least 100,000 per mL of blood

See 13 more

Exclusion Criteria

My cancer has spread to distant parts of my body after standard treatment.

I am currently taking medication to prevent blood clots.

I haven't had any cancer except for non-invasive types or highly curable ones in the last 5 years.

See 7 more

Treatment Details

Interventions

Ifetroban Sodium (Thromboxane A2 Receptor Antagonist)
Placebo (Other)

Trial OverviewThe trial is testing Ifetroban Sodium against a placebo to see if it makes platelets less sticky and reduces the chance of cancer spreading. It's for patients whose cancers are likely to recur and spread after initial treatment.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Group 1 (ifetroban)Experimental Treatment1 Intervention

ifetroban capsule (250mg) will be taken by mouth daily.

Group II: Group 2 (placebo)Placebo Group1 Intervention

Placebo capsule (250mg) will be taken by mouth daily.